Pages that link to "Q47799946"
Jump to navigation
Jump to search
The following pages link to Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria (Q47799946):
Displaying 50 items.
- Maintenance chemotherapy for ovarian cancer (Q24201758) (← links)
- Maintenance bioimmunotherapy for epithelial ovarian cancer (Q24234761) (← links)
- Maintenance chemotherapy for ovarian cancer (Q24235427) (← links)
- Maintenance chemotherapy for ovarian cancer (Q24241605) (← links)
- Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer (Q24650026) (← links)
- Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study (Q25257587) (← links)
- Chemotherapy of ovarian cancer in elderly patients (Q26771397) (← links)
- An Investigation of the Shortcomings of the CONSORT 2010 Statement for the Reporting of Group Sequential Randomised Controlled Trials: A Methodological Systematic Review (Q26777085) (← links)
- Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer (Q26783551) (← links)
- Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea (Q27011282) (← links)
- Perioperative and Maintenance Therapy After First-Line Therapy as Paradigms for Drug Discovery in Urothelial Carcinoma (Q27024948) (← links)
- Advanced ovarian cancer: what should be the standard of care? (Q27852053) (← links)
- The promise and perils of 'targeted therapy' of advanced ovarian cancer (Q28282889) (← links)
- The dangers of "cross-trial" and "cross-retrospective experience" comparisons: examples employing data in the peer-reviewed ovarian cancer literature (Q31106869) (← links)
- Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients (Q33314684) (← links)
- Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities (Q33315604) (← links)
- Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer (Q33364075) (← links)
- Sequential gemcitabine-carboplatin followed by paclitaxel-carboplatin in the first-line treatment of advanced ovarian cancer: A phase II study (Q33369125) (← links)
- A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada [...] (Q33370081) (← links)
- Phase 2 study of intraperitoneal topotecan as consolidation chemotherapy in ovarian and primary peritoneal carcinoma (Q33379831) (← links)
- A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma (Q33407574) (← links)
- The feasibility of administering varying high-dose consolidation hyperthermic intraperitoneal chemotherapy with carboplatin in the treatment of ovarian carcinoma (Q33419382) (← links)
- Consolidation hyperthermic intraperitoneal chemotherapy and maintenance chemotherapy following laparoscopic cytoreductive surgery in the treatment of ovarian carcinoma (Q33419612) (← links)
- Prostasin may contribute to chemoresistance, repress cancer cells in ovarian cancer, and is involved in the signaling pathways of CASP/PAK2-p34/actin (Q33705325) (← links)
- Cell-penetrating, guanidinium-rich molecular transporters for overcoming efflux-mediated multidrug resistance (Q34011165) (← links)
- Current status of maintenance therapy for advanced ovarian cancer. (Q34271924) (← links)
- Clinical trials and progress with paclitaxel in ovarian cancer (Q34510070) (← links)
- Clinicodemographic factors influencing outcomes in patients with low-grade serous ovarian carcinoma (Q34626854) (← links)
- Prognosis and conditional disease-free survival among patients with ovarian cancer (Q34692286) (← links)
- Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels (Q34838655) (← links)
- Immunization with synthetic VEGF peptides in ovarian cancer (Q34901858) (← links)
- A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study (Q35033234) (← links)
- Practical considerations in ovarian cancer chemotherapy (Q35076260) (← links)
- Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer (Q35114915) (← links)
- Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer (Q35154140) (← links)
- Consolidation/maintenance chemotherapy for ovarian cancer (Q35548330) (← links)
- Abagovomab: An Anti-Idiotypic CA-125 Targeted Immunotherapeutic Agent for Ovarian Cancer (Q35564007) (← links)
- Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab (Q35842690) (← links)
- Update on Gynecologic Oncology Group (GOG) trials in ovarian cancer (Q35968742) (← links)
- First-line therapy for ovarian carcinoma: what's next? (Q35968748) (← links)
- Novel agents in epithelial ovarian cancer (Q35968752) (← links)
- Role of pegylated liposomal doxorubicin in ovarian cancer (Q35979245) (← links)
- The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer (Q36063233) (← links)
- Monoclonal antibody therapy of ovarian cancer (Q36066157) (← links)
- Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation (Q36076716) (← links)
- Consolidation therapy with weekly paclitaxel infusion in advanced epithelial ovarian cancer and primary peritoneal cancer: an extended follow-up (Q36137624) (← links)
- Systemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approaches (Q36144210) (← links)
- Emerging drugs for ovarian cancer (Q36150652) (← links)
- Treatment options in the management of ovarian cancer (Q36150781) (← links)
- Clinical utility of targeted treatments in the management of epithelial ovarian cancer (Q36171268) (← links)